For a better experience please change your browser to CHROME, FIREFOX, OPERA or Internet Explorer.
PTSD Study Advances Medical Cannabis Research

PTSD Study Advances Medical Cannabis Research

January 29, 2018

An interview with Sue Sisley

Abstract / Synopsis: 

The lack of controlled clinical studies on the effectiveness of cannabis to treat medical conditions has been a major concern for the industry. In January 2017, the nonprofit organization Multidisciplinary Association for Psychedelic Studies (MAPS) began a clinical study of the use of smoked whole-plant marijuana to treat symptoms of post-traumatic stress disorder (PTSD) in U.S. veterans. The study, now ongoing at the Scottsdale Research Institute in Phoenix, Arizona, has been approved by the Public Health Service, the Food and Drug Administration, the Drug Enforcement Agency (DEA), and institutional review boards, and is funded by a $2.1 million grant to MAPS from the Colorado Department of Public Health and Environment. Sue Sisley, MD, is the site principal investigator on the study, and Marcel Bonn-Miller, PhD, is the coordinating principal investigator. Sisley spoke to us about the study and the overall environment for medical cannabis research in the United States.


leave your comment

Your email address will not be published. Required fields are marked *

Subscribe to our Newsletter

Join us today to receive regular updates on current trends and events

Select list(s)*


Flight Comparison

Find the best accommodation deals

All you need for your Trip

Are you 18 or older? This website requires you to be 18 years of age or older. Please verify your age to view the content, or click "Exit" to leave.